U.S. Stock News

Orion S.A. ( NYSE:OEC ) shares have had a really impressive month, gaining 26% after a shaky period beforehand. But the...

The Rivian Automotive, Inc. ( NASDAQ:RIVN ) share price has softened a substantial 26% over the previous 30 days...

Unfortunately for some shareholders, the Alpha Teknova, Inc. ( NASDAQ:TKNO ) share price has dived 29% in the last...

Unfortunately for some shareholders, the Claritev Corporation ( NYSE:CTEV ) share price has dived 26% in the last...

Key Insights Creative Global Technology Holdings' significant insider ownership suggests inherent interests in...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Investors may wish to note that the First Senior VP & Director of Mortgage Lending of Unity Bancorp, Inc. , Vincent...

Ideally, your overall portfolio should beat the market average. But in any portfolio, there will be mixed results...

While CSW Industrials, Inc. ( NYSE:CSW ) might not have the largest market cap around , it saw a significant share...

Siebert Financial Corp. ( NASDAQ:SIEB ) shareholders won't be pleased to see that the share price has had a very rough...

CarMax, Inc. ( NYSE:KMX ) shares have had a really impressive month, gaining 27% after a shaky period beforehand...

Key Insights Significantly high institutional ownership implies Aldeyra Therapeutics' stock price is sensitive to their...

Some THOR Industries, Inc. ( NYSE:THO ) shareholders may be a little concerned to see that the Senior VP & COO, W...

If you are wondering whether Revolution Medicines at around US$120 per share reflects its real worth, you are not alone. This article is designed to help you frame that question clearly. The stock closed at US$120.28 recently, with returns of 1.4% over 7 days, 52.7% over 30 days, 52.2% year to date, 198.5% over 1 year and 337.1% over 3 years, which naturally raises questions about how expectations and risk are being priced in. Recent news flow around Revolution Medicines has focused on its...

SunOpta Inc. ( NASDAQ:STKL ) shareholders are no doubt pleased to see that the share price has bounced 25% in the last...

It might be of some concern to shareholders to see the Atlanticus Holdings Corporation ( NASDAQ:ATLC ) share price down...

The Bank of New York Mellon Corporation ( NYSE:BK ) stock is about to trade ex-dividend in four days. The ex-dividend...

Balchem's (NASDAQ:BCPC) stock is up by a considerable 12% over the past three months. Since the market usually pay for...

Heritage Global Inc. ( NASDAQ:HGBL ) shareholders should be happy to see the share price up 15% in the last month. But...

Universal Electronics Inc. ( NASDAQ:UEIC ) shareholders are no doubt pleased to see that the share price has bounced...

Key Insights Significantly high institutional ownership implies Inseego's stock price is sensitive to their trading...

CG Oncology (CGON) is back in focus after accelerating the topline data timeline for its Phase 3 PIVOT-006 trial, the first randomized study for intermediate-risk non muscle invasive bladder cancer patients. See our latest analysis for CG Oncology. The accelerated PIVOT-006 timeline sits against a strong recent run, with a 30 day share price return of 40.23% and a 1 year total shareholder return of 88.20%, suggesting momentum has been building around the story. If CG Oncology’s progress has...

Earlier this week, UBS analyst Leonardo Olmos upgraded Millicom International Cellular (TIGO) to a buy rating, citing increased confidence in the company’s growth outlook as it expands telecom services across Latin America and pursues acquisitions in Ecuador and Uruguay. This shift in analyst sentiment highlights how Millicom’s regional expansion and service diversification are increasingly shaping market perceptions of its longer-term prospects. We’ll now examine how UBS’s renewed...

In recent days, Centessa Pharmaceuticals reported new preclinical data showing its selective OX2R agonist reduced behavioral despair and improved wakefulness in animal models of major depressive disorder, while also outlining plans to broaden its orexin pipeline across neuropsychiatric conditions with high unmet need. Coupled with strong analyst support, leadership changes, and a planned US$250,000,000 public offering to fund late-stage trials, these developments highlight how Centessa is...